Abstract
Most animals respond to the i.v. administration of 5-hydroxytryptamine (5-HT) initially with a decrease in heart rate, generally via similar mechanisms and receptors. In isolated heart preparations or in whole animals without vagal influences, 5-HT usually increases heart rate and, sometimes, cardiac contractility, but a variety of mechanisms and receptors appear to be involved in different species. Although the cardiac effects of 5-HT have been studied extensively, the precise nature of the receptors involved is emerging only now (Saxena, 1986). This is particularly due to the availability of selective drug tools and the characterization of 5-HT receptor subtypes into 5-HT1-like, 5-HT2 and 5-HT3 receptors (see Bradley et al., 1986). This present article reviews the mechanisms and the nature of the 5-HT receptors mediating the cardiac effects of 5-HT (Table 15.1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bom, A. H., Duncker, D. J., Saxena, P. R. and Verdouw, P. D. (1988). 5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor. Br. J. Pharmacol., 93, 663–671
Bradley, P. B., Engel, G., Feniuk, W., Fozard, J. R., Humphrey, P. P. A., Middlemiss, D. N., Mylecharane, E. J., Richardson, B. P. and Saxena, P. R. (1986). Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology, 25, 563–576
Chiba, S. (1977). Pharmacologic analysis of chronotropic and inotropic responses to 5-hydroxytryptamine in the dog heart. Jap. J. Pharmacol., 27, 727–734
Connor, H. E., Feniuk, W., Humphrey, P. P. A. and Perren, M. J. (1986). 5-Carboxamidotryptamine is a selective agonist at 5-HT receptors mediating vasodilatation and tachycardia in anaesthetized cats. Br. J. Pharmacol., 87, 417–426
Dhasmana, K. M., de Boer, H. J., Banerjee, A. K. and Saxena, P. R. (1988). Analysis of the tachycardiac response to 5-hydroxytryptamine in the spinal guinea-pig. Eur. J. Pharmacol., 145, 67–73
Eglen, R. M., Park, K. C. and Whiting, R. L. (1985). Analysis of the positive chronotropic action of 5-HT on the isolated guinea-pig atria. Br. J. Pharmacol., 86, 658P
Feniuk, W., Humphrey, P. P. A. and Watts, A. D. (1981). An analysis of the mechanism of 5-hydroxytryptamine-induced vasopressor responses in ganglion-blocked anaesthetized dogs. J. Pharm. Pharmacol., 33, 155–160
Fozard, J. R. (1984a). MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol., 326, 36–44
Fozard, J. R. (1984b). Neuronal 5-HT receptors in the periphery. Neuropharmacol-ogy, 23, 1473–1486
González Alvarez, R. and GarcÃa RodrÃguez, M. (1977). Sobre el mecanismo de accion de la serotonina en la auricula aislada de hamster. I. Serotonina: amina de accion mixta. Acta Physiol. Lat. Am., 27, 239–247
Göthert, M., Schlicker, E. and Kollecker, P. (1986). Receptor-mediated effects of serotonin and 5-methoxytryptamine on noradrenaline release in the rat vena cava and in the heart of the pithed rat. Naunyn-Schmiedeberg’s Arch. Pharmacol., 332, 124–130
Kaumann, A. J. (1986). Further differences between 5-HT receptors of atrium and ventricle in cat heart. Br. J. Pharmacol., 89, 546P
Kimura, T. and Satoh, S. (1983). Presynaptic inhibition by serotonin of cardiac sympathetic transmission in dogs. Clin. Exp. Pharmacol. Physiol., 10, 535–542
LeMessurier, D. H., Schwartz, C. J. and Whelan, R. F. (1959). Cardiovascular effects of intravenous infusions of 5-hydroxytryptamine in man. Br. J. Pharmacol., 14, 246–250
Mawe, G. M, Branchek, T. A. and Gershon, M. D. (1986). Peripheral neural serotonin receptors: Identification and characterization with specific antagonists and agonists. Proc. Natl Acad. Sci. U.S.A., 83, 9799–9803
Richardson, B. P., Engel, G., Donatsch, P. and Stadler, P. (1985). Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature, 316, 126–131
Saxena, P. R. (1986). Nature of the 5-hydroxytryptamine receptors in mammalian heart. Prog. Pharmacol., 6, 173–185
Saxena, P. R. (1988). Further characterization of 5-hydroxytryptamine1-like receptors mediating tachycardia in the cat: no apparent relationship to known subtypes of the 5-hydroxytryptamine1 binding site. Drug Devel. Res., 13, 245–258
Saxena, P. R. and Lawang, A. (1985). A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors. Arch. Int. Pharmacodyn., 217, 235–252
Saxena, P. R., Heiligers, J., Mylecharane, E. J. and Tio, R. (1985a). Excitatory 5-hydroxytryptamine receptors in the cat urinary bladder are of the M- and 5-HT2type. J. Auton. Pharmacol., 5, 101–107
Saxena, P. R., Mylecharane, E. J. and Heiligers, J. (1985b). Analysis of the heart rate effects of 5-hydroxytryptamine in the cat; mediation by 5-HT1-like receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol., 330, 121–129
Trendelenburg, U. (1960). The action of histamine and 5-hydroxytryptamine on isolated mammalian atria. J. Pharmacol. Exp. Ther., 130, 450–460
Walker, R. J. (1985). The pharmacology of serotonin receptors in invertebrates. In Green, A. R. (Ed.), Neuropharmacology of Serotonin, Oxford University Press, Oxford, pp. 366–408
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Copyright information
© 1989 The editors and contributors
About this chapter
Cite this chapter
Saxena, P.R. (1989). Cardiac Actions of 5-Hydroxytryptamine. In: Mylecharane, E.J., Angus, J.A., de la Lande, I.S., Humphrey, P.P.A. (eds) Serotonin. Satellite Symposia of the IUPHAR 10th International Congress of Pharmacology. Palgrave Macmillan, London. https://doi.org/10.1007/978-1-349-10114-6_15
Download citation
DOI: https://doi.org/10.1007/978-1-349-10114-6_15
Publisher Name: Palgrave Macmillan, London
Print ISBN: 978-1-349-10116-0
Online ISBN: 978-1-349-10114-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)